India, Jan. 26 -- Merck (MRK) Tuesday announced new interim data from the Phase 2a trial in adults evaluating the safety, tolerability and pharmacokinetics of islatravir, the company's investigational oral nucleoside reverse transcriptase translocation inhibitor, for pre-exposure prophylaxis.
Pre-exposure prophylaxis or PrEP is a way for people who do not have HIV but who are at very high risk of getting HIV to prevent HIV infection by taking a pill every day.
Interim findings demonstrate that once-monthly oral islatravir achieved the pre-specified efficacy PK threshold for PrEP at both of the two doses studied.
In the interim analysis using blinded data, both monthly doses of islatravir were found to have an acceptable tolerability prof...